Using Platinum Agents in Different Settings of TNBC
Fabrice André, MD, PhD, professor in the Department of Medical Oncology at the Institut Gustave Roussy in Villejuif, France, addresses questions regarding the use of platinum regimens for patients with triple-negative breast cancer (TNBC). He discusses 2 platinum agents, cisplatin and carboplatin, and when it is recommended that these agents be used.
Fabrice André, MD, PhD, professor in the Department of Medical Oncology at the Institut Gustave Roussy in Villejuif, France, addresses questions regarding the use of platinum regimens for patients with triple-negative breast cancer (TNBC). He discusses 2 platinum agents, cisplatin and carboplatin, and when it is recommended that these agents be used.
One factor for platinum treatments includes the presence ofBRCAmutations. If a patient presents a germline mutation for eitherBRCA1orBRCA2, a platinum agent such as cisplatin or carboplatin can be used in the frontline setting, according to the results of the TNT trial. However, for individuals that do not show signs of these mutations, platinum agents should not be used in the first-line setting.
Jhaveri Compares Safety and Duration of Adjuvant CDK4/6 Inhibitors in HR+ Breast Cancer
December 22nd 2024During a Case-Based Roundtable® event, Komal Jhaveri, MD, FACP, discussed dosing and toxicity concerns with the approved CDK4/6 inhibitor regimens used in the adjuvant setting for patients with hormone receptor–positive breast cancer.
Read More
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
